Synthesis and antitumor activity of the immunoconjugate BR96-Dox
Authors:
- R.A. FirestoneRFR.A. Firestone
- D. WillnerDWD. Willner
- S.J. HofsteadSHS.J. Hofstead
- H.D. KingHKH.D. King
- T. KanekoTKT. Kaneko
- G.R. BraslawskyGBG.R. Braslawsky
- R.S. GreenfieldRGR.S. Greenfield
- P.A. TrailPTP.A. Trail
- S.J. LaschSLS.J. Lasch
- A.J. HendersonAHA.J. Henderson
- A.M. CasazzaACA.M. Casazza
- I. HellströmIHI. Hellström
- 1 May 1996
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 39 (2-3) , 251-259
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Orthotopic is orthodox: Why are orthotopic‐transplant metastatic models different from all other models?Journal of Cellular Biochemistry, 1994
- (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicinBioconjugate Chemistry, 1993
- Cure of Xenografted Human Carcinomas by BR96-Doxorubicin ImmunoconjugatesScience, 1993
- Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5‐fluorouracilInternational Journal of Cancer, 1992
- Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activityCancer Immunology, Immunotherapy, 1991
- New hydrazone derivatives of Adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicityBioconjugate Chemistry, 1991
- Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spreadInternational Journal of Cancer, 1991